NCT07465666 A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
| NCT ID | NCT07465666 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-10-15 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-10-15 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Eligibility Criteria
Inclusion criteria: 1. Adult male or female patients (≥18 years). 2. Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology \[AHA/ACC\] guidelines and/or the 2024 European Society of Cardiology \[ESC\] guidelines). 3. Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi. 4. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi. Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion. 5. Patients willing to provide written informed consent to participate in the study. Exclusion criteria: 1. Patients with malignant or severe hypertension (systolic blood pressure \[SBP\] ≥180 mmHg, diastolic blood pressure \[DBP\] ≥110 mmHg) at baseline. 2. Patients with secondary causes of hypertension, as determined by the treating physician. 3. Patients with a history of, or at risk of developing, angioedema. 4. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m\^2). 5. Pregnant or lactating women. 6. Patients with serum potassium level ≥5.5 mmol/L at baseline.
Contact & Investigator
Novartis Pharmaceuticals
STUDY DIRECTOR
Novartis Pharmaceuticals
Frequently Asked Questions
Who can join the NCT07465666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07465666 currently recruiting?
Yes, NCT07465666 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07465666 trial being conducted?
This trial is being conducted at Abu Dhabi, United Arab Emirates, Dubai, United Arab Emirates, Fujairah, United Arab Emirates, Ras al-Khaimah, United Arab Emirates.
Who is sponsoring the NCT07465666 clinical trial?
NCT07465666 is sponsored by Novartis Pharmaceuticals. The principal investigator is Novartis Pharmaceuticals at Novartis Pharmaceuticals. The trial plans to enroll 500 participants.